NiKem Research s.r.l.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NiKem Research s.r.l.
The Italian government has certified NiKem Research's bioanalysis facilities, allowing it to support its clients' preclinical pharmacokinetics and toxicology studies. The company was already offering hit validation and multiparametric lead optimisation services, along with other services related to drug discovery.
In some ways, neuropathic pain seems an odd choice of focus for a small start-up. It comes in many forms and its mechanisms are poorly understood. Moreover, the size and strength of those with stakes in the pain market might be another reason for emerging companies to steer clear. Fortunately, they're not. The unmet need is huge: Only one in two patients actually get some relief from existing drugs, in part because their mechanisms of action are fairly generalized. There remains plenty to be done in identifying and understanding the precise mechanisms behind the various flavors of neuropathic pain. For those whocan figure out new approaches to pain or new uses in pain for failed or overlooked compounds -- the companies profiled in this issue are doing both -- there's a big reward at the end: Sales of neuropathic pain therapies in the seven major pharmaceutical markets reached nearly $5 billion in 2007.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Nikem spun out its R&D assets with about a years' worth of funds to pursue development of its neuropathic pain and Parkinson's disease compounds, which are currently in preclinical development. The company, Brane, is seeking Series A funding.
- Contract Research, Toxicology Testing-CRO
Drug Discovery Tools
- Drug Discovery Tools